Clinical Trials Logo
  1. Home
  2. AIDS Dementia Complex
  3. NCT02678767

Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

AIDS Dementia Complex Clinical Trial

Official title:
Ferumoxytol-enhanced Imaging and Quantitative Susceptibility Mapping in neuroAIDS

Clinical Trial Summary

This project will investigate the ability of a novel MRI contrast agent to identify and quantitate ongoing monocyte/macrophage (M/MΦ)-mediated inflammation in the brains of HIV-infected individuals.

Clinical Trial Description

HIV-associated neurocognitive disorders (HAND) continue to be prevalent despite effective combination antiretroviral therapy (cART) and have a significant impact on morbidity and quality of life. Monocytes/macrophages (M/MΦ) are believed to play a critical role in the pathogenesis of HAND. Neuroimaging HIV research has not focused on assessing M/MΦ-mediated inflammation in the brain. Currently, no neuroimaging modality exists that can define the extent of active inflammation due to M/MΦ in HAND either as a clinical diagnostic tool or to assist in defining objective improvement in clinical trials addressing HAND. Ferumoxytol is an ultra-small iron oxide MRI contrast agent avidly taken up by circulating M/MΦ. The investigators hypothesize that ferumoxytol-based imaging can identify ongoing inflammation due to perivascular M/MΦ which is believed to represent a key pathologic correlate of HAND. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02678767
Study type Interventional
Source University of Hawaii
Contact
Status Completed
Phase Phase 2
Start date February 2015
Completion date September 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT00002246 - A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex Phase 3
Completed NCT02159027 - Maraviroc and NeuroAIDS Pathogenesis Phase 2/Phase 3
Completed NCT00000867 - A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC) Phase 2
Terminated NCT00459693 - PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD) N/A
Completed NCT02128828 - Effect of Cenicriviroc on HIV Neurocognitive Impairment Phase 2
Completed NCT00000738 - Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1 Phase 1
Completed NCT00002209 - Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy Phase 1
Completed NCT00000709 - An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts Phase 3
Completed NCT00000702 - A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection Phase 3
Completed NCT00002044 - A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases N/A
Completed NCT00002163 - A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex Phase 3
Completed NCT00000657 - Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex Phase 2